Welcome to our dedicated page for Ambiq Micro SEC filings (Ticker: AMBQ), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Ambiq Micro, Inc. (NYSE: AMBQ) SEC filings page on Stock Titan provides access to the company’s official regulatory disclosures as filed with the U.S. Securities and Exchange Commission. As a fabless semiconductor company focused on ultra-low-power edge AI solutions, Ambiq uses these filings to report material events, financial results, governance changes, and equity compensation matters related to its SPOT®-based technology business.
Investors can review Form 8-K current reports in which Ambiq furnishes quarterly earnings press releases, detailing net sales, gross profit, operating expenses, net loss, and non-GAAP measures such as non-GAAP gross profit and non-GAAP net loss. These filings also describe business drivers like product mix, geographic revenue shifts, and demand for Apollo and other edge AI platforms. Additional 8-K items document events such as the completion of Ambiq’s initial public offering on the New York Stock Exchange and subsequent board and executive compensation decisions.
Over time, users can expect this page to include annual reports on Form 10-K and quarterly reports on Form 10-Q, which typically provide more detailed discussions of Ambiq’s SPOT technology, Apollo and Atomiq product families, risk factors, and management’s analysis of financial condition and results of operations. These core filings are central for understanding how Ambiq describes its ultra-low-power edge AI strategy and market exposure.
Stock Titan enhances these documents with AI-powered summaries that highlight key points from lengthy filings, helping readers quickly identify important changes in revenue trends, operating expenses, or capital structure. The platform also tracks insider-related filings such as Form 4, where available, so users can monitor equity awards and transactions involving Ambiq’s directors and executive officers.
By combining real-time updates from EDGAR with AI-generated insights, this page offers a focused view into AMBQ’s regulatory history, financial reporting practices, and governance developments, all grounded in the company’s official SEC submissions.
Esaka Fumihide reported acquisition or exercise transactions in this Form 4 filing.
Ambiq Micro, Inc. reported that Chief Executive Officer Fumihide Esaka received a grant of 160,616 restricted stock units (RSUs) of common stock at no cost as equity compensation. Each RSU represents one share upon settlement. Following this award, he directly holds 391,189 shares. The RSUs vest over time: 25% of the shares are scheduled to vest on September 1, 2027, and the remaining shares vest in equal quarterly installments thereafter, contingent on his continued service under the company’s 2025 Equity Incentive Plan.
Ambiq Micro, Inc. develops ultra-low power semiconductor systems-on-chip and software that run AI on edge devices such as wearables, medical and industrial sensors, and smart home products. Its proprietary SPOT platform is designed to cut power consumption two to five times versus conventional designs.
For the year ended December 31, 2025, Ambiq generated net sales of $72.5 million compared with $76.1 million in 2024, and reported a net loss of $36.5 million versus $39.7 million, with an accumulated deficit of $356.7 million as of December 31, 2025. Research and development expenses were $38.5 million in 2025 and $37.2 million in 2024.
The company relies on a fabless model, using TSMC and a small group of packaging and test providers, and is highly dependent on a concentrated set of large customers and distributors. It is shifting away from lower-margin Mainland China business, where sales declined from 50% of net sales in 2024 to 9% in 2025. Ambiq highlights extensive risk factors, including continued losses, customer concentration, supply chain dependence, evolving AI and data privacy regulation, and cybersecurity threats.
Ambiq Micro, Inc. reported fourth quarter and full year 2025 results showing improving profitability metrics despite slightly lower annual revenue. Full year 2025 net sales were $72.5 million versus $76.1 million in 2024, but GAAP gross margin rose to 44.3% from 31.9%, lifting gross profit to $32.1 million, the highest in company history.
For Q4 2025, net sales reached $20.7 million, the highest quarter of the year, with GAAP gross margin of 42.7% and non-GAAP gross margin of 45.5%. Full year GAAP net loss attributable to common stockholders improved to $36.5 million, while non-GAAP net loss narrowed to $20.9 million.
Ambiq strengthened its balance sheet, ending 2025 with $140.3 million in cash and cash equivalents and converting preferred stock to common following an upsized IPO and follow-on offerings. For Q1 2026, the company guides net sales of $21.0–$22.0 million, non-GAAP gross margin of 44.0–45.0%, and non-GAAP net loss per share between ($0.39) and ($0.33) on 20.38 million weighted average shares.
Ambiq Micro director-related entity exercises warrants for common shares. Matter Venture Partners Fund I, L.P., for which HSIEH Wen Hsuan exercises sole voting and dispositive control, exercised a warrant for 238,931 shares of Ambiq Micro common stock through a derivative conversion at an exercise price of $12.60 per share. After the transaction, the fund held 633,920 shares of Ambiq Micro common stock indirectly attributable to HSIEH Wen Hsuan.
Ambiq Micro, Inc. Chief Executive Officer and director Esaka Fumihide reported exercising stock options and acquiring additional common shares. On October 7, 2025, a stock option for 53,660 shares with a $5.88 exercise price was exercised, converting into 53,660 shares of common stock at $5.88 per share.
Following this transaction, Esaka Fumihide directly owned 230,573 shares of Ambiq Micro common stock, and the reported option position was reduced to zero. The option had vested over time, with vesting beginning in 2016 and subject to continued service and the issuer’s repurchase rights.
Ambiq Micro, Inc. director Joseph A. Tautges reported a sale of company stock. On January 26, 2026, he sold 7,800 shares of Ambiq Micro common stock at $31 per share in a single open-market transaction. After this sale, he beneficially owns 48,746 common shares, held in direct ownership form.
Ambiq Micro, Inc. director and Chief Technology Officer Hanson Scott McLean reported selling 10,000 shares of common stock on 01/26/2026 at $31 per share. After this transaction, he beneficially owns 122,818 shares of Ambiq Micro common stock, held directly.
Ambiq Micro, Inc. is registering 2,679,600 shares of common stock at a public offering price of $31.00 per share, including 2,636,651 shares sold by the company and 42,949 shares sold by existing stockholders, with an underwriter option for up to 401,940 additional shares. Ambiq expects gross proceeds of $83,067,600, yielding $76,832,010 in proceeds to the company and $1,251,534 to selling stockholders before expenses.
The company designs ultra‑low power semiconductor SoCs based on its SPOT® platform to run AI workloads at the edge with two to five times lower power consumption than conventional designs, and its products power over 290 million devices. Net sales were $76.1 million in 2024 and $65.5 million in 2023, with a net loss of $39.7 million in 2024 and $50.3 million in 2023. For 2025, Ambiq preliminarily estimates net sales of $71.77–$72.47 million, with gross margin improving from 31.9% in 2024 to an estimated 43.7% in 2025 and non‑GAAP gross margin to 44.3–44.6%.
Ambiq is shifting away from Mainland China, where 2024 net sales of $38.0 million are expected to fall sharply in 2025, while net sales outside Mainland China are estimated to rise to about $65.3–$66.4 million and represent roughly 91–91.6% of total net sales.
Ambiq Micro, Inc. released preliminary, estimated unaudited financial results for the year ended December 31, 2025. The company expects net sales between $71,770 thousand and $72,470 thousand, with net sales outside Mainland China between $65,331 thousand and $66,368 thousand.
Net sales in Mainland China are estimated between $6,102 thousand and $6,439 thousand, representing about 8.4% to 9.0% of total net sales, while sales outside Mainland China represent about 91.0% to 91.6%. Estimated gross profit ranges from $31,359 thousand to $31,667 thousand, with a gross margin of 43.7%.
On a non-GAAP basis, Ambiq estimates gross profit between $31,792 thousand and $32,300 thousand and non-GAAP gross margin between 44.3% and 44.6%. These figures are preliminary, based on internal records, have not been audited or reviewed by KPMG LLP, and may change after completion of the year-end closing and audit.